The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
Seasoned pharmaceutical R&D leader takes on an expanded leadership role to drive innovation and strengthen Hetero’s advanced formulation development capabilities
New AMF Series combines industry-leading 1000:1 turndown capability, predictive diagnostics, and digital connectivity in a footprint no larger than a standard Post-it Note pad
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
Highlights India’s advances in pharmacopoeial science, regulatory standards, and global harmonization efforts at the 16th International Meeting of World Pharmacopoeias
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Approval paves the way for expansion in North America’s growing vascular access market, with innovative SlipStream technology designed to simplify catheter insertion and enhance patient care
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Subscribe To Our Newsletter & Stay Updated
